Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review - Open Journal of Endocrine and Metabolic Diseases

OJEMD > Vol.10 No.10, October 2020

Open Journal of Endocrine and Metabolic Diseases

Volume 10, Issue 10 (October 2020)

ISSN Print: 2165-7424 ISSN Online: 2165-7432

Google-based Impact Factor: 0.3 Citations

Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review ()

HTML XML

Download as PDF (Size: 716KB) PP. 137-146

DOI: 10.4236/ojemd.2020.1010013 518 Downloads 3,141 Views Citations

Author(s)

Pedro Luis Imbeth-Acosta¹, Nehomar Pájaro-Galvis^2*, Víctor Leal-Martinez³, Jorge Rico-Fontalvo⁴, Rodrigo Daza-Arnedo⁵, Orlando Castañeda-López⁶, María Cardona-Blanco⁷, Karen Mercado-Anillo⁸, José Lucas-Daza⁹, Christian Perez-Calvo¹⁰, Jhonatan Hernández-Meza¹¹, Álvaro Barraza-Pombo¹², Marianela Florez-Ortega¹³, Jorge Hoyos-Fortich¹⁴, Isabella Uparella-Gulfo¹¹

Affiliation(s)

¹Blas de Lezo Clinic, Cartagena, Bolívar, Colombia.
²Faculty of Health Sciences, University of Sinú, Cartagena, Bolívar, Colombia.
³New Bocagrande Hospital, Cartagena, Bolívar, Colombia.
⁴Colombian Association of Nephrology, Medellín, Colombia.
⁵Colombian Association of Nephrology, Cartagena, Colombia.
⁶Endocrinos SAS, Cartagena, Colombia.
⁷Renal Unit B. Braun, Medellín, Antioquia, Colombia.
⁸University of Cartagena, Cartagena, Bolívar, Colombia.
⁹Colombian Association of Nephrology, Ibagué, Colombia.
¹⁰Caribbean University Hospital, Cartagena, Colombia.
¹¹University of Sinu, Cartagena, Colombia.
¹²Epidemiologist, Blas de Lezo Clinic, Cartagena, Colombia.
¹³Naval Hospital, Cartagena, Colombia.
¹⁴Rafael Nuñez University, Cartagena, Colombia.

ABSTRACT

Chronic liver disease (CLD) refers to a structural and functional change of the liver, which modifies the pharmacokinetics of multiple drugs, including hypoglycemic agents. This alteration depends on the severity degree of the liver disease, clinical characteristics of the patient, and comorbidities presence such as kidney disease and drug biochemistry. Insulin is considered a safe therapeutic strategy in patients with CLD, however, for many oral hypoglycemic agents, its use and dose adjustment will depend on the Child-Pugh score, based on the risk of hypoglycemia in this type of patient.

KEYWORDS

Cirrhosis, Hypoglycemic Agents, Pharmacokinetics (MeSH)

Share and Cite:

Imbeth-Acosta, P. , Pájaro-Galvis, N. , Leal-Martinez, V. , Rico-Fontalvo, J. , Daza-Arnedo, R. , Castañeda-López, O. , Cardona-Blanco, M. , Mercado-Anillo, K. , Lucas-Daza, J. , Perez-Calvo, C. , Hernández-Meza, J. , Barraza-Pombo, Á. , Florez-Ortega, M. , Hoyos-Fortich, J. and Uparella-Gulfo, I. (2020) Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review. Open Journal of Endocrine and Metabolic Diseases, 10, 137-146. doi: 10.4236/ojemd.2020.1010013.

Cited by